Complex metabolic protection as a modern strategy for the management of type 2 diabetes mellitus
AbstractThe primary task of managing patients with type 2 diabetes meLLitus is complex cardiometabolic protection, which can be implemented by including innovative drugs in therapy: agonists of glucagonlike peptide-1 receptors and inhibitors of type 2 sodium glucose cotransporter. The review pays great attention to the high conjugation of disorders of carbohydrate metabolism and overweight, the role of adipose tissue adipokines in the regulation of pathological adipostat. The most relevant data concerning the mechanism of action, multiple pleiotropic effects, the evidence base of the most recent glucagon-like peptide 1 agonist, semaglutide, with an emphasis on positive modification of cardiovascular prognosis and reduction of excess body weight are presented. The obvious additional advantage of this molecule is its high safety profile and comfortable dosing schedule - once a week.
Keywords:semaglutide, cardiovascular diseases, adipose tissue, body weight
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Ametov A.S., Tsygankova O.V. Complex metabolic protection as a modern strategy for the management of type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (2): 93-104. DOI: https://doi.org/10.33029/2304-9529-2021-10-2-93-104 (in Russian)
REFERENCES
1. Williams R., Colagiuri S., Chan J., et al. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: 2019. URL: URL: https://www.diabetesatlas.org (date of access April 26, 2021)
2. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., et al. Diabetes epidemiology in Russia: what has changed over the decade? Terapevtich-eskiy arkhiv [Therapeutic Archive]. 2019; 91 (10): 4-13. DOI: https://doi.org/10.26442/00403660.2019.10.000364 (in Russian)
3. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (2): 104-12. DOI: https://doi.org/10.14341/DM2004116-17 (in Russian)
4. Ametov A.S., Pugovkina Ya.V., Vovk PS. Insulin therapy is a century-long success story. Focus on basal insulin. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (1): 26-33. DOI: https://doi.org/10.33029/2304-9529-2021-10-1-26-33 (in Russian)
5. Ametov A.S., Nevol’nikova A.O., Tertychnaya E.A., Mishra O.A. Du-laglutide, a glucagon-like peptide-1 receptor agonist: in the search for survival molecule. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 49-58. DOI: DOI: https://doi.org/10.33029/2304-9529-2020-9-2-49-58 (in Russian)
6. Tsygankova O.V., Veretyuk V.V. Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (4): 81-92. DOI: https://doi.org/10.15829/1560-4071-2021-4436 (in Russian)
7. Tsygankova O.V., Veretyuk V.V., Mareev V. Yu. Modification of the of the cardiometabolic profile using combined therapy of the angiotensin receptor-neprilysin inhibitor and empagliflozin in comorbid patients with Chronic Heart Failure and type 2 Diabetes Mellitus. Kardiologiya [Cardiology]. 2020; 60 (5): 146-52. DOI: https://doi.org/10.18087/cardio.2020.5.n840 (in Russian)
8. World Health Organization (WHO). Newsletter. Obesity and overweight: 2020. URL: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight (date of access April 26, 2021) (in Russian)
9. Shalnova S.A., Drapkina O.M. Contribution of the ESSE-RF study to preventive healthcare in Russia. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (3): 2602. DOI: https://doi.org/10.15829/1728-8800-2020-2602 (in Russian)
10. Bhupathiraju S.N., Hu F.B. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118 (11): 1723-35. DOI: https://doi.org/10.1161/CIRCRESAHA.115.3068258
11. Wadden T.A. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014; 22 (1): 5-13.
12. Galstyan G.R., Shestakova E.A., Sklyanik I.A. Obesity and type 2 diabetes: can we find a compromised treatment solution? Sakharniy diabet [Diabetes Mellitus]. 2017;20(4):270-278. DOI: https://doi.org/10.14341/DM8726 (in Russian)
13. Shestakova M.V., Mokrysheva N.G., Dedov I.I. Course and treatment of diabetes mellitus in the context of COVID-19. Sakharniy diabet [Diabetes Mellitus]. 2020; 23 (2): 132-9. DOI: https://doi.org/10.14341/DM12418 (in Russian)
14. Holman N., Knighton P., Kar P., et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8 (10): 823-33. DOI: https://doi.org/10.1016/S2213-8587(20)30271-0
15. Smati S., et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: results from the CORONADO study. Diabetes Obes Metab. 2021; 23 (2): 391-403.
16. Kusminski C.M., Bickel PE., Scherer P.E. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov. 2016; 15 (9): 639-60. DOI: https://doi.org/10.1038/nrd.2016.75
17. Smekal A., Vaclavik J. Adipokines and cardiovascular disease: a comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017; 161 (1): 31-40. DOI: https://doi.org/10.5507/bp.2017.002
18. Lau W.B., Ohashi K., Wang Y., et al. Role of adipokines in cardiovascular disease. Circ J. 2017; 81 (7): 920-8. DOI: https://doi.org/10.1253/circj.CJ-17-0458
19. Ruscica M., Baragetti A., Catapano A.L., Norata G.D. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Nutr Metab Cardiovasc Dis. 2017; 27 (5): 379-95. DOI: https://doi.org/10.1016/j.numecd.2016.12.005
20. Jaganathan R., Ravindran R., Dhanasekaran S. Emerging role of adi-pocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes. 2018; 42 (4): 446-56. DOI: https://doi.org/10.1016/j.jcjd.2017.10.040
21. Norata G.D., Tavori H., Pirillo A., et al. Biology of proprotein con-vertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res. 2016; 112 (1): 429-42. DOI: https://doi.org/10.1093/cvr/cvw194
22. Shi J., Fan J., Su Q., Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol (Lausanne). 2019; 10: 703. DOI: https://doi.org/10.3389/fendo.2019.00703
23. Fang H., Judd R.L. Adiponectin regulation and function. Compr Physiol. 2018; 8 (3): 1031-63. DOI: https://doi.org/10.1002/cphy.c170046
24. Pobozheva I.A., Panteleeva A.A., Polyakova E.A., et al. Subcutaneous adipose tissue omentin-1 in coronary artery disease patients. Meditsins-kaya genetika [Medical Genetics]. 2020; 19 (11): 21-30. DOI: https://doi.org/10.25557/2073-7998.2020.11.21-30 (in Russian)
25. Draganova A.S., Polyakova E.A., Kolodina D.A., et al. Concentration omentin-1 in the serum of patients with coronary heart disease. Transly-atsionnaya meditsina [Translational Medicine]. 2019; 6 (6): 5-13. DOI: https://doi.org/10.18705/2311-4495-2019-6-6-5-13 (in Russian)
26. Ametov A.S., Pyanykh O.P., Golodnikov I.I. Selected lectures from the XVIII World Congress Insulin Resistance «Diabetes & Cardiovascular Disease». Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (1): 8-13. DOI: https://doi.org/10.33029/2304-9529-2021-10-1-8-13 (in Russian)
27. Dedov I.I., Romantsova T.I., Shestakova M.V. Rational approach to patients treatment with type 2 diabetes and obesity: results of the AllRussian observational program «AURORA». Ozhirenie i metabolism [Obesity and Metabolism]. 2018; 15 (4): 48-58. DOI: https://doi.org/10.14341/OMET10076 (in Russian)
28. American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes - 2021. Diabetes Care. 2021; 44 (suppl 1): S 100-10. DOI: https://doi.org/10.2337/dc21-S008
29. Dedov I.I., Shestakova M.V., Mayorov A. Yu., Vikulova O.K., et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A. Yu. 9th edition. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (S 1): 1-112. DOI: https://doi.org/10.14341/DM221S1 (in Russian)
30. Tsygankova O.V., Veretyuk V.V., Ametov A.S. Incretins today: multiple effects and therapeutic potential. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (1): 70-8. DOI: https://doi.org/10.14341/DM9841 (in Russian)
31. Chung W.K., Erion K., Florez J.C., et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43 (7): 1617-35. DOI: https://doi.org/10.2337/dci20-0022
32. Scheen A.J., Paquot N. Management of patients with type 2 diabetes at cardiovascular and renal risk: ESC versus ADA-EASD [Traitement des patients diabetiques de type 2 a risque cardio-renal: ESC versus ADA-EASD]. Rev Med Suisse. 2020; 16 (703): 1478-82.
33. Marx N., Davies M.J., Grant PJ., et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021; 9 (1): 46-52. DOI: https://doi.org/10.1016/S2213-8587(20)30343-0
34. Schernthaner G., Shehadeh N., Ametov A.S., et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020; 19 (1): 185. DOI: https://doi.org/10.1186/s12933-020-01154-w
35. Ahren B., Atkin S.L., Charpentier G., et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018; 20 (9): 2210-9. DOI: https://doi.org/10.1111/dom.13353
36. Nauck M.A., Quast D.R., Weferset J., et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021; 46: 101102. DOI: https://doi.org/10.1016/j.molmet.2020.101102
37. Sorli C., Harashima S.I., Tsoukas G.M., et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5 (4): 251-60. DOI: https://doi.org/10.1016/S2213-8587(17)30013-X
38. Ahren B., Masmiquel L., Kumar H., et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomized trial. Lancet Diabetes Endocrinol. 2017; 5 (5): 341-54. DOI: https://doi.org/10.1016/S2213-8587(17)30092-X
39. Ahmann A.J., Capehorn M., Charpentier G., et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41 (2): 258-66. DOI: https://doi.org/10.2337/dc17-0417
40. Aroda V.R., Bain S.C., Cariou B., et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5 (5): 355-66. DOI: https://doi.org/10.1016/S2213-8587(17)30085-2
41. Rodbard H.W., Lingvay I., Reed J., et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018; 103 (6): 2291-301. DOI: https://doi.org/10.1210/jc.2018-00070
42. Marso S., Bain S.C., Consoli A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375 (19): 1834-44. DOI: https://doi.org/10.1056/NEJMoa1607141
43. Pratley R.E., Aroda V.R., Lingvay I., et al. SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6 (4): 275-86. DOI: https://doi.org/10.1016/S2213-8587(18)30024-X
44. Lingvay I., Catarig A.M., Frias J.P., et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7 (11): 83444. DOI: https://doi.org/10.1016/S2213-8587(19)30311-0
45. Zinman B., Bhosekar V., Busch R., et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019; 7 (5): 356-67. DOI: https://doi.org/10.1016/S2213-8587(19)30066-X
46. Capehorn M.S., Catarig A.-M., Furbergb J.K., et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020; 46 (2): 100-9. DOI: https://doi.org/10.1016/j.diabet.2019.101117
47. Demidova T. Yu., Izmailova M. Ya., Lobanova K.G. Innovative hypoglycemic technologies in the practice of general physician. Terapiya [Therapy]. 2020; (8): 64-73. DOI: https://doi.org/10.18565/therapy.2020.8.64-73 (in Russian)
48. Bulgakova S., Romanchuk N., Treneva, E. Glucagon-like peptide 1, brain, neurodegenerative diseases: a modern view. Byulleten’ nauki i praktiki [Bulletin of Science and Practice]. 2020; 6 (4): 153-72. DOI: https://doi.org/10.33619/2414-2948/53/19 (in Russian)
49. Zhang L., Zhang L., Li L., Holscher C. Semaglutide is neuroprotective and reduces asynuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinsons Dis. 2019; 9 (1): 157-71. DOI: https://doi.org/10.3233/JPD-181503
50. Peter R., Bain S.C. Safety of injectable semaglutide for type 2 diabetes. Expert Opin Drug Saf. 2020; 19 (7): 785-98. DOI: https://doi.org/10.1080/14740338.2020.1772230
51. Secher A., Vrang N., Bjerre Knudsen L. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124 (10): 4473-88. DOI: https://doi.org/10.1172/JCI7527651
52. Iacobellis G., Villasante Fricke A.C. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020; 4 (4): 1-9. DOI: https://doi.org/10.1210/jendso/bvz042
53. Kobalava Zh.D., Kokhan E.V. Semaglutide for the management of type 2 diabetes: clinical evidence, cardioprotective effects, and guidelines. Kardiologiya [Cardiology]. 2020; 60 (9): 122-33. DOI: https://doi.org/10.18087/cardio.2020.9.n1274 (in Russian)
54. American Diabetes Association. ADA standards of diabetes care 2021. J Clin Appl Res Educ. 2021; 44 (1): S 21-226.
55. Karpov Yu.A., Starostina E.G. Semaglutide (Ozempic) from the Point of View of Endocrinologist and Cardiologist: the Possibilities of Glucagonlike Peptide-1 Analogues are far from Exhausted. Novosti kardiologii [News of Cardiology]. 2019; (4). DOI: https://doi.org/10.24411/2076-4189-2019-12170 (in Russian)
56. Nidorf S.M., et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020; 383 (19): 1838-47.
57. Tardif J.-C., et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381 (26): 2497-505.
58. Miyagawa J., et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015; 17 (10): 974-83. DOI: https://doi.org/10.1111/dom.12534
59. State Register of Medicinal Products [Electronic resource]. URL: https://grls.rosminzdrav.ru (date of access April 25, 2021) (in Russian)